Literature DB >> 2566907

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

R M Hudziak1, G D Lewis, M Winget, B M Fendly, H M Shepard, A Ullrich.   

Abstract

The HER2/c-erbB-2 gene encodes the epidermal growth factor receptorlike human homolog of the rat neu oncogene. Amplification of this gene in primary breast carcinomas has been show to correlate with poor clinical prognosis for certain cancer patients. We show here that a monoclonal antibody directed against the extracellular domain of p185HER2 specifically inhibits the growth of breast tumor-derived cell lines overexpressing the HER2/c-erbB-2 gene product and prevents HER2/c-erbB-2-transformed NIH 3T3 cells from forming colonies in soft agar. Furthermore, resistance to the cytotoxic effect of tumor necrosis factor alpha, which has been shown to be a consequence of HER2/c-erbB-2 overexpression, is significantly reduced in the presence of this antibody.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2566907      PMCID: PMC362707          DOI: 10.1128/mcb.9.3.1165-1172.1989

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  41 in total

1.  Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1.

Authors:  R Philip; L B Epstein
Journal:  Nature       Date:  1986 Sep 4-10       Impact factor: 49.962

2.  Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line.

Authors:  S Fukushige; K Matsubara; M Yoshida; M Sasaki; T Suzuki; K Semba; K Toyoshima; T Yamamoto
Journal:  Mol Cell Biol       Date:  1986-03       Impact factor: 4.272

Review 3.  Growth factor receptor tyrosine kinases.

Authors:  Y Yarden; A Ullrich
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

Review 4.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities.

Authors:  J Le; J Vilcek
Journal:  Lab Invest       Date:  1987-03       Impact factor: 5.662

Review 5.  Cachectin and tumour necrosis factor as two sides of the same biological coin.

Authors:  B Beutler; A Cerami
Journal:  Nature       Date:  1986 Apr 17-23       Impact factor: 49.962

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  Effects of growth factors on the antiproliferative activity of tumor necrosis factors.

Authors:  B J Sugarman; G D Lewis; T E Eessalu; B B Aggarwal; H M Shepard
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

8.  Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors.

Authors:  R Derynck; D V Goeddel; A Ullrich; J U Gutterman; R D Williams; T S Bringman; W H Berger
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

9.  Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.

Authors:  J L Urban; H M Shepard; J L Rothstein; B J Sugarman; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

10.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.

Authors:  L Coussens; T L Yang-Feng; Y C Liao; E Chen; A Gray; J McGrath; P H Seeburg; T A Libermann; J Schlessinger; U Francke
Journal:  Science       Date:  1985-12-06       Impact factor: 47.728

View more
  176 in total

1.  Positive and negative regulation of endogenous genes by designed transcription factors.

Authors:  R R Beerli; B Dreier; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 2.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

Review 3.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

Review 4.  The ERBB network: at last, cancer therapy meets systems biology.

Authors:  Yosef Yarden; Gur Pines
Journal:  Nat Rev Cancer       Date:  2012-07-12       Impact factor: 60.716

5.  Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment.

Authors:  Smitha Reddy; Calvin C Shaller; Mohan Doss; Irina Shchaveleva; James D Marks; Jian Q Yu; Matthew K Robinson
Journal:  Clin Cancer Res       Date:  2010-12-21       Impact factor: 12.531

6.  Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism.

Authors:  Balveen Kaur; Sarah M Cork; Eric M Sandberg; Narra S Devi; Zhaobin Zhang; Philip A Klenotic; Maria Febbraio; Hyunsuk Shim; Hui Mao; Carol Tucker-Burden; Roy L Silverstein; Daniel J Brat; Jeffrey J Olson; Erwin G Van Meir
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

7.  Development of anti-p185HER2 immunoliposomes for cancer therapy.

Authors:  J W Park; K Hong; P Carter; H Asgari; L Y Guo; G A Keller; C Wirth; R Shalaby; C Kotts; W I Wood
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

Review 8.  The use of nanoparticulates to treat breast cancer.

Authors:  Xiaomeng Tang; Welley S Loc; Cheng Dong; Gail L Matters; Peter J Butler; Mark Kester; Craig Meyers; Yixing Jiang; James H Adair
Journal:  Nanomedicine (Lond)       Date:  2017-09-04       Impact factor: 5.307

9.  Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival.

Authors:  Peter Vajkoczy; Pjotr Knyazev; Andrea Kunkel; Hans-Holger Capelle; Sandra Behrndt; Hendrik von Tengg-Kobligk; Fabian Kiessling; Uta Eichelsbacher; Marco Essig; Tracy-Ann Read; Ralf Erber; Axel Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

10.  ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner.

Authors:  M A Olayioye; D Graus-Porta; R R Beerli; J Rohrer; B Gay; N E Hynes
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.